BioLineRx Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for BioLineRx Ltd. (BLRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-9.22-60.61-24.95-27.05-30.02-25.45-22.96
Depreciation & Amortization3.991.330.650.700.930.000.55
Stock Based Compensation1.142.322.251.501.270.000.00
Change in Working Capital-21.8215.201.24-0.54-1.290.00-1.71
Change in Accounts Receivable-2.12-0.360.000.000.000.000.00
Change in Inventory-1.19-1.950.000.000.000.000.00
Change in Accounts Payable-5.515.511.89-0.56-1.720.000.00
Change in Other Working Capital-0.04-0.960.450.020.430.000.00
Other Operating Activities-19.9612.40-1.293.485.302.78-0.52
Net Cash from Operating Activities-43.87-22.61-26.24-101.57-23.21-66.21-24.19
Investing Activities
Capital Expenditures-0.05-0.120.320.100.000.07-0.17
Acquisitions0.000.000.000.000.000.001.50
Purchases of Investments29.431.74-44.00-38.1316.670.000.00
Sales/Maturities of Investments0.00-0.1848.3239.870.000.0018.27
Other Investing Activities0.000.000.000.000.000.000.00
Net Cash from Investing Activities29.371.444.0139.7816.6748.809.56
Financing Activities
Debt Repayment-14.94-1.99-3.05-3.57-3.36-1.10-0.41
Common Stock Issued16.3817.0423.4950.4121.2220.303.83
Other Financing Activities0.020.000.000.000.000.000.00
Net Cash from Financing Activities20.6615.0620.4457.7517.8719.1913.10
Summary
Effect of Forex Changes on Cash0.02-0.22-0.610.210.000.00-0.17
Net Change in Cash6.18-6.33-1.80-4.0511.531.79-1.54
Cash at Beginning of Period4.2610.5912.9916.835.303.405.11
Cash at End of Period10.444.2611.1912.7816.635.193.40
Free Cash Flow-43.93-22.72-26.56-101.67-23.21-66.28-34.41
Supplemental Disclosures
Interest Paid10.391.110.590.680.990.000.00